Furthermore, microglial deletion of Mib2 reduces the microglial activation, neuroinflammation, and brain damage after ischemic stroke, suggesting that Mib2 might be a potential therapeutic target in stroke treatment (Fig. 6I). This evidence concerns the gene MIB2 and ischemic stroke.